GFH603: A molecular glue–like allosteric activator of the KEAP1-CUL3 E3 ligase complex for targeting NRF2-activated tumors



Preclinical evaluation of GFH276 monotherapy and combination therapy for RAS-mutant tumors

[illegible]

Introduction

- [illegible]
- [illegible]
- [illegible]



GFH276 recruits CypA to target active GTP-bound RAS proteins.

MOA of GFH276

GFH276 effectively inhibits RAS signaling in RAS-dependent cells.

p-ERK IC_{50} in cell lines

[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Conclusions

Introduction

- [illegible]
- [illegible]

Results

GFS784 is a novel EGFR-targeted ADC equipped with a pan-RAS(ON) inhibitor payload.